Deaths in the large β blocker mortality analyses
| USCP | CIBIS II | MERIT-HF | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Placebo (n = 398) | Carvedilol (n = 696) | Placebo (n = 1320) | Bisoprolol (n = 1327) | Placebo (n = 2001) | Metoprolol (n = 1990) | |||||
| All | 31 | 22 | 228 | 156 | 217 | 145 | ||||
| Cardiovascular (%)9-150 | 31 (100) | 20 (91) | 161 (71) | 119 (76) | 203 (94) | 128 (88) | ||||
| Sudden (%)9-151 | 15 (48) | 12 (55) | 83 (36) | 48 (31) | 132 (61) | 79 (54) | ||||
| Pump failure9-153(%)9-152 | 13 (42) | 5 (23) | 47 (21) | 36 (23) | 58 (27) | 30 (21) | ||||
↵9-150 CIBIS II hazard ratio 0.71, 95% CI 0.56 to 0.90, p = 0.0049; MERIT-HF relative risk 0.62, 95% CI 0.50 to 0.78, p = 0.0003.
↵9-151 CIBIS II hazard ratio 0.56, 95% CI 0.39 to 0.80, p = 0.0011; MERIT-HF relative risk 0.45, 95% CI 0.45 to 0.78, p = 0.0002.
↵9-152 CIBIS II hazard ratio 0.74, 95% CI 0.48 to 1.14, p = 0.17; MERIT-HF relative risk 0.51, 95% CI 0.33 to 0.79, p = 0.0023.
↵9-153 Pump failure equates to progressive or worsening heart failure.